Overview

• Soligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expenses

• Company reports no revenue for Q3 2025, same as Q3 2024

• Soligenix has $10.5 mln cash, providing runway through 2026

Outlook

• Soligenix anticipates top-line results from Phase 3 HyBryte™ study in H2 2026

• Company plans to carefully allocate resources to achieve strategic goals

• Soligenix exploring partnerships and financing to advance late-stage pipeline

Result Drivers

• CLINICAL TRIAL EXPENSES - Increased net loss attributed to higher costs from ongoing clinical trials, particularly the second confirmatory Phase 3 CTCL trial

• CASH MANAGEMENT - Co has $10.5 mln cash, focused on strategic resource allocation and exploring funding options

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Soligenix Inc is $17.50, about 92.7% above its November 6 closing price of $1.28

Press Release: ID:nPn5tY9PYa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)